Tisotumab vedotin-tftv is a Tissue Factor (TF) directed antibody drug conjugate (ADC) comprised of a human anti-TF IgG1-kappa antibody conjugated to the microtubule-disrupting agent monomethyl auristatin E (MMAE) via a protease-cleavable vc (valine-citrulline) linker. The monoclonal antibody is produced in a mammalian cell line (Chinese hamster ovary). MMAE and the linker are produced by chemical synthesis. Each monoclonal antibody molecule carries an average of 4 MMAE molecules. Tisotumab vedotin-tftv has an approximate molecular weight of 153 kDa. Tisotumab vedotin has the potential for use in research of solid tumors mainly in cervical cancer. This product is for research use only.
Product Details |
Species Reactivity | Human |
---|
Type | Antibody-drug conjugate |
---|
ADC antibody | Tisotumab (tissue factor III (thromboplastin)/CD142) |
---|
ADC cytotoxin (drug) | MMAE |
---|
Immunogen | Human TF/CD142 |
---|
DAR (Drug to Antibody Ratio) | 4.2 |
---|
Purity | 99% |
---|
Molecular Weight | 153kDa |
---|
Storage Condition | Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles. |
---|
Storage Buffer | 1xPBS |